Dutch identify bluetongue variant in livestock, no available vaccine
Adds more detail and background from 3rd paragraph
AMSTERDAM, Oct 11 (Reuters) -Animal health authorities in the Netherlands have discovered infections in livestock of a bluetongue variant, BTV12, for which no vaccine is available, the Dutch government said on Friday.
The cases were found in a sheep and a cow and its calf at two farms in the centre of the Netherlands on Thursday.
Bluetongue can be deadly for domestic ruminants such as sheep, cattle and goats.
A new variant of the disease, BTV3, has been circulating in Europe since late last year, leading to vaccination campaigns in affected countries, including France and the Netherlands.
The Dutch agriculture ministry said the BTV12 variant had been found previously in countries outside Europe, but that these were the first known cases in the Netherlands.
It said it was too early to say whether a new vaccine was needed, but added it had informed vaccine producers of the cases.
Reporting by Bart Meijer; editing by Philippa Fletcher and Ros Russell
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
